BBIO vs. MRNA: BridgeBio Pharma vs. Moderna Stock Comparison
How do BridgeBio Pharma (BBIO) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BridgeBio Pharma (BBIO) and Moderna (MRNA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BBIO | MRNA |
|---|---|---|
| Name | BridgeBio Pharma Inc. | Moderna Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 14.47 billion USD | 101.48 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 27, 2019 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| Total Return (1Y) | 22.70% | 1,031.66% |
| Total Return (3Y, Annualized) | 40.97% | 58.68% |
| Total Return (5Y, Annualized) | 8.25% | 3.23% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| Volatility (1Y, Annualized) | 44.39% | 194.88% |
| Beta (5Y) | 0.93 | 1.08 |
| Max Drawdown (5Y) | -89.79% | -93.93% |
| Avg. Volume (3M) | 2.68M | 21.61M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.41 | 5.27 |
| Sortino Ratio (1Y) | 0.63 | 20.44 |
Profitability
ROE (TTM)
BridgeBio Pharma (BBIO) has no ROE value reported for this period; Moderna (MRNA) reports a negative figure of -39.00%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- BBIO
- --
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.00%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- MRNA
- -39.00%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both BridgeBio Pharma (BBIO) at -59.84% and Moderna (MRNA) at -141.43% report negative net margin values, usually indicating net losses over the period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-59.84%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BBIO
- -59.84%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-141.43%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- MRNA
- -141.43%
Operating Margin (TTM)
Both BridgeBio Pharma (BBIO) at -3.30% and Moderna (MRNA) at -557.93% report negative operating margin values, usually indicating operating losses over the period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-3.30%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- BBIO
- -3.30%
- Q1
- -78.82%
- Min
- -207.40%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-557.93%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- MRNA
- -557.93%
Profitability Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| ROE (TTM) | -- | -39.00% |
| ROA (TTM) | -13.97% | -13.26% |
| Net Margin (TTM) | -59.84% | -141.43% |
| Operating Margin (TTM) | -3.30% | -557.93% |
| Gross Margin (TTM) | 94.34% | -66.02% |
Growth
Revenue Growth
BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Moderna (MRNA) at -39.92% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Neither BridgeBio Pharma (BBIO) nor Moderna (MRNA) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| Revenue Growth (YoY) | 126.26% | -39.92% |
| Revenue Growth (3Y CAGR) | 86.30% | -53.30% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both BridgeBio Pharma (BBIO) at 2.09 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.09
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BBIO
- 2.09
- Min
- 0.10
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.30
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRNA
- 2.30
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Moderna (MRNA) carries debt-to-equity ratio of 0.19 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- BBIO
- --
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- MRNA
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 2.09 | 2.30 |
| Debt / Equity (MRQ) | -- | 0.19 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither BridgeBio Pharma (BBIO) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Moderna (MRNA) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BBIO
- --
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- MRNA
- --
P/S Ratio (TTM)
BridgeBio Pharma (BBIO) at 15.31 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.31
- Max
- 58.18
- Q3
- 25.77
- BBIO
- 15.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.55
- Max
- 58.18
- MRNA
- 45.55
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Moderna (MRNA) reports 11.58, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.59
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BBIO
- -5.59
- Min
- -5.59
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.58
- Max
- 13.53
- MRNA
- 11.58
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BBIO | MRNA |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 15.31 | 45.55 |
| P/B Ratio (MRQ) | -5.59 | 11.58 |
| Free Cash Flow Yield (TTM) | -1.98% | 0.29% |